decisionhealth Newsletters, Part B News - 2003 Issue 9 (September)
Lots of new drugs coming - how to bill for approved drugs that lack codes
Subscribe or sign in to view the full article.
Article Overview
This piece covers emerging Medicare payment issues for newly approved drugs and biologicals, especially injectable products that may not yet have assigned billing codes. It is aimed at billing and coding professionals, oncology and specialty practices, and anyone tracking payer handling of new drugs. The article explains the broad reporting steps practices may need to consider, the role of carrier guidance, and the impact of newly assigned codes for certain drugs.
Why This Topic Matters
New drugs can enter the market before standard billing codes are available, creating reimbursement and claims-processing questions for practices. Understanding the general coding and payer workflow helps reduce denials and supports timely payment for approved products.
What You Will Learn
- How emerging drugs and biologicals can create billing issues when codes are not yet assigned
- Which general Medicare billing resources and payer confirmations may be relevant for unlisted drug claims
- Why newly assigned drug codes may not be recognized by every payer at the same time
- What kinds of specialties may be affected by new injectable therapies
Who Should Read This
- Medical coders
- Billing specialists
- Practice administrators
- Oncology practices
- Specialty practices
- Healthcare revenue cycle staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com